BD uplifts FY26 revenue outlook based on steady portfolio performance

In a reversal from its antecedently reported quarter, Becton Dickinson and Company (BD) has lifted its fiscal twelvemonth 2026 (FY26) nett outlook during the merchandise of its Q2 2026 financials.

Reporting revenues of astir $4.7bn successful Q2 of FY26, indicative of a 5.2% uptick year-over-year (YoY), BD present anticipates its FY26 net per stock to autumn successful the $12.52 to $12.72 per stock range, up from the $12.35 to $12.65 scope outlined previously.

BD elected to trim its FY26 outlook upon the merchandise of its Q1 FY26 net successful February 2026. At the time, BD said the determination had been made to relationship for the company’s divestment of its biosciences & diagnostic solutions concern to Waters, which completed connected 9 February 2026.

BD released its financials up of marketplace open. The revised FY26 outlook seems to person satisfied investors, arsenic BD’s banal was up by 0.26% to $145 per stock arsenic astatine 7:20am ET connected 7 May, up from $144.76 previously.

Reflecting connected the company’s Q2 show and explaining the rationale for its gross outlook’s uplift, BD CEO Tom Polen said: “Based connected our first‑half show and improved visibility into the equilibrium of the year, we are raising our full‑year adjusted EPS guidance and reaffirming our gross maturation expectations. We stay focused connected disciplined execution of our New BD strategy, including advancing our commercialized and innovation initiatives crossed cardinal maturation platforms, expanding margins, and delivering connected our superior allocation framework, each to thrust sustainable long‑term shareholder value."

In Q2, each of BD’s concern segments witnessed YoY growth. Medical essentials represented the biggest revenue-generating conception astatine astir $1.65bn, corresponding to a 4.7% uptick YoY. This was followed by interventional and connected attraction arsenic the 2nd and 3rd biggest areas for BD, achieving gross of astir $1.36bn and $1.1bn, equating to YoY maturation of 7.3% and 4.9%, respectively.

Other medtech companies that person precocious released their latest financials see continuous glucose monitoring (CGM) specializer Dexcom and Stryker. Both companies maintained their 2026 outlook, with Stryker doing truthful successful spite of a challenging Q1 that was constrained by a cyberattack that disrupted its planetary operations. GE HealthCare, meanwhile, chose to trim its 2026 outlook connected the ground of rising freight costs.

"BD uplifts FY26 gross outlook based connected dependable portfolio performance" was primitively created and published by Medical Device Network, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.